Strahlentherapie und Onkologie最新文献

{"title":"DEGRO statement on the FAST-Forward trial: 10-year data of ultrahypofractionated radiation therapy for breast cancer.","authors":"C Matuschek, K Borm, J Hörner-Rieber, K Dellas, N M Duma, J Dunst, R Fietkau, T Hehr, M Pazos, V Strnad, W Budach, M D Piroth, D Krug","doi":"10.1007/s00066-025-02481-1","DOIUrl":"10.1007/s00066-025-02481-1","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1-4"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12819474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research with cancer registry data in radiation oncology-current possibilities and perspectives : A narrative review.","authors":"Jörg Andreas Müller, Ahmed Bedir, Alexander Katalinic, Florian Oesterling, Aleksandra Graw, Alexander Kluttig, Stefanie Corradini, Dirk Vordermark, Daniel Medenwald","doi":"10.1007/s00066-025-02486-w","DOIUrl":"10.1007/s00066-025-02486-w","url":null,"abstract":"<p><strong>Clinical background: </strong>Cancer registry data are an essential resource for population-based oncology research and quality assurance in Germany. With the revision of the Federal Cancer Registry Data Act in 2021, for the first time, a legal basis was created for the development of a nationwide clinical cancer dataset. This registry offers new opportunities for research, particularly in radiation oncology.</p><p><strong>Objective: </strong>This review aims to provide an overview of the current possibilities of and challenges to using German cancer registry data in radiation oncology, with a focus on data structure, missing data, access procedures, and methodological aspects for scientific research.</p><p><strong>Methods: </strong>We examined legal frameworks, data access procedures, and the structure of the nationwide basic oncology dataset (oBDS), particularly the components relevant to radiotherapy (RT). The completeness and comprehensiveness of RT data across federal states were assessed using national registry data from the German Center for Cancer Registry Data (ZfKD) for the years 2020-2022.</p><p><strong>Results: </strong>The cancer registries provide structured data on RT through the oBDS, including treatment intent, technique, target area, and side effects. However, significant variability in terms of completeness and reporting standards persists among federal states. Missing data rates remain high in some regions, particularly for key RT parameters such as treatment technique, the relationship to surgery, and boost application. Methodological challenges for scientific use include handling missing data, confounding, immortal time bias, and exposure misclassification.</p><p><strong>Conclusion: </strong>Despite existing limitations, cancer registry data in Germany represent a valuable resource for real-world research in radiation oncology. They allow for large-scale population-based studies beyond the constraints of clinical trials. With improved data harmonization, methodological rigor, and future data linkages (e.g., to health insurance data), registry-based studies can contribute significantly to evidence-based decision-making and quality improvement in radiation oncology.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"13-22"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12819489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation Oncology Representation in German Evidence-Based Oncological Guidelines: 2025 Analysis of Participation and Parity from Women in Radiation Oncology Working Group of the German Society of Radiation Oncology (DEGRO).","authors":"Angela Besserer, Sally Mutiara, Monika Nothacker, Andrea Wittig, Juliane Hörner-Rieber, Lara Caglayan, Daniel Habermehl, Stefan Höcht, Michael van Kampen, Cordula Petersen, Ursula Nestle, Mechthild Krause, Dirk Vordermark, Maike Trommer","doi":"10.1007/s00066-025-02498-6","DOIUrl":"https://doi.org/10.1007/s00066-025-02498-6","url":null,"abstract":"<p><strong>Background: </strong>In Germany, the development of evidence based medical guidelines is overseen by the Association of the Scientific Medical Societies (AWMF). Ensuring balanced representation across medical specialties and genders is essential for generating comprehensive, equitable, and unbiased treatment recommendations. This study evaluates the involvement of radiation oncology (RO) specialists and assesses gender representation within the panels of German oncological guidelines.</p><p><strong>Methods: </strong>We analysed all oncological guidelines in the AWMF registry (n = 93/820). Data were collected from AWMF's registry, the German Society for Radiation Oncology (DEGRO) website, and affiliated organizations including the Working Group for Radiation Oncology (ARO) and the Professional Association of German Radiation Oncologists (BVDST). Gender distribution, academic qualifications, and participation rates were analysed.</p><p><strong>Results: </strong>Of 93 oncological AWMF guidelines, RO panel members participated in 71 (76.3%), with particularly high representation in S3 (highest standard of quality and reliability) guidelines (92.5%). A total of 2795 panelists were represented in 85 analysable oncological guidelines, with 28.3% being female. Among the 255 RO panelists, the proportion of women is significantly higher with 34.5% (p < 0.05), with varying distribution across organizations: DEGRO 38.6%, ARO 31.7%, and BVDST 28.2%. Academic qualifications regarding all panelists differed significantly by gender (p < 0.001) with a high proportion of professors being male (81.3%), while women were disproportionately represented among those no academic title (62.6%).</p><p><strong>Conclusions: </strong>RO demonstrates strong representation in German oncological guideline development, in contrast to international trends where the specialty is frequently underrepresented. Nonetheless, consistent with patterns observed across other medical disciplines and healthcare systems, gender disparities remain evident: women constitute roughly one-third of overall panel members. These findings establish an important reference point for tracking future progress toward achieving gender equity in the formulation of oncological guidelines.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145715859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative therapy patterns for thymic carcinoma with complete resection: retrospective analysis of 120 patients.","authors":"Yan Gao, Xingwen Fan, Hong Zheng, Yingshan Cui, Qiong Yi, Yaqi Li, Yulei Pei, Kailiang Wu","doi":"10.1007/s00066-025-02410-2","DOIUrl":"10.1007/s00066-025-02410-2","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to determine the role of postoperative adjuvant therapy in patients with thymic carcinoma following complete resection.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of patients with stage I-III or N1+ thymic carcinomas who underwent complete resection at our center between 2006 and 2020. Data on the clinical characteristics and postoperative adjuvant therapies were collected.</p><p><strong>Results: </strong>One hundred and twenty patients were enrolled. Five (4.2%) patients received only postoperative chemotherapy, 36 (33.0%) received only postoperative radiotherapy, 75 (62.5%) received postoperative chemoradiotherapy, and four (3.3%) did not receive any postoperative therapy. During a median follow-up period of 65 months, disease failure was observed in 46 (38.3%) patients, and 28 (23.3%) patients died. The 5‑year disease-free survival (DFS) and overall survival (OS) rates were 58.7 and 81.4%, respectively. Patients who underwent different postoperative therapies exhibited varying prognoses. Radiotherapy reduced the risks of failure (p < 0.001) and death (p < 0.001), whereas chemotherapy did not (p = 0.198 and 0.260 respectively). Subgroup analyses revealed that stage III/IV patients who received chemotherapy had a lower relapse risk (p = 0.045) and improved OS (p = 0.064). Multivariate analysis demonstrated that radiotherapy alone (hazard ratio [HR], 0.24; p = 0.023) independently predicted OS.</p><p><strong>Conclusions: </strong>Adjuvant radiotherapy should be recommended for patients with thymic carcinoma who have undergone complete resection. Further exploration is needed to clarify the role of adjuvant chemotherapy.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1269-1278"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12701033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy of localized orbital mantle cell lymphoma: a SEER database analysis of long-term outcomes.","authors":"Pierre Loap, Youlia Kirova, Rémi Dendale","doi":"10.1007/s00066-025-02404-0","DOIUrl":"10.1007/s00066-025-02404-0","url":null,"abstract":"<p><strong>Introduction: </strong>Primary orbital lymphomas are predominantly low-grade subtypes, such as extranodal marginal zone lymphomas (MALT) and follicular lymphomas, which are highly radiosensitive. Mantle cell lymphoma (MCL), although less common, is an aggressive high-grade subtype with an intermediate-to-poor prognosis. While systemic therapies are standard for MCL, data on the efficacy of radiotherapy in localized orbital MCL are limited. This study evaluates the long-term outcomes of radiotherapy for localized orbital MCL using the Surveillance, Epidemiology, and End Results (SEER) database.</p><p><strong>Materials and methods: </strong>This retrospective study analyzed cases of localized orbital MCL treated with radiotherapy between 2000 and 2021 identified in the SEER database. Demographic, clinical, and survival data were extracted. The primary endpoints were overall (OS) and cancer-specific survival (CSS), estimated using the Kapla-Meier method and Cox proportional hazards models. Statistical analyses were conducted using R software (R Foundation, Vienna, Austria), with a significance threshold set at p < 0.05.</p><p><strong>Results: </strong>Among 13,662 patients with localized primary orbital lymphomas, 63 (0.5%) cases were histologically confirmed as MCL. Of these, 35 patients (55.6%) received radiotherapy. The age-adjusted incidence rate of orbital MCL was 0.033 per 1,000,000 person-years (95% CI: 0.025-0.042). Patients were predominantly elderly (42.9% were over 80 years old) and male (male-to-female ratio of 2.18 : 1; p = 0.012). With a median follow-up of 91 months (range: 4-237 months), the median OS was 113 months. The 5‑, 10-, and 15-year OS rates were 76.5% (95% CI: 62.7-93.4%), 48.2% (32.9%-70.6%), and 42.8% (27.4%-66.9%), respectively. Median CSS was not reached, with 5‑, 10-, and 15-year CSS rates of 98.0% (95% CI: 78.0-100.0%), 83.4% (69.5%-100.0%), and 83.4% (69.5%-100.0%), respectively. Chemotherapy did not show a significant impact on survival.</p><p><strong>Conclusion: </strong>Radiotherapy achieves excellent long-term survival outcomes for localized orbital MCL, particularly in elderly and frail patients who may not tolerate systemic therapies. These findings support radiotherapy as an effective therapeutic option for this rare lymphoma subtype. Future multicenter studies are warranted to optimize radiotherapy protocols and improve patient outcomes.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1254-1258"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modern approaches to radiotherapy in primary cutaneous lymphomas: insights and recommendations from the DEGRO dermato-oncology working group.","authors":"Khaled Elsayad, Dora Correia, Ulrike Theiß, Andrea Baehr, Angela Besserer, Oliver Micke, Burkhard Greve, Cora Waldstein, Stefanie Corradini, Daniel Habermehl, Laila König, Kathrin Hering, Sebastian Adeberg, Hans Theodor Eich","doi":"10.1007/s00066-025-02453-5","DOIUrl":"10.1007/s00066-025-02453-5","url":null,"abstract":"<p><p>The growing use of reduced-dose radiotherapy in patients with primary cutaneous lymphoma is a promising development. Nevertheless, the absence of controlled clinical trials to ascertain standardized doses for each specific type constitutes a significant impediment to the advancement of this field. This expert opinion strongly advocates for advancements in radiation oncology practice that address the unique complexities of primary cutaneous lymphoma. By refining our methodologies, we can optimize patient care and outcomes in this dynamic field.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1249-1253"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12701040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of fetal dose exposure by modern radiation therapy in pregnant patients with supradiaphragmatic Hodgkin lymphoma-a phantom-based simulation.","authors":"Gina M Smeets, Isabel Vogt, Heidi Wolters, Christopher Kittel, Dominik A Hering, Fabian M Troschel, Gabriele Reinartz, Burkhard Greve, Uwe Haverkamp, Michael Oertel, Hans T Eich","doi":"10.1007/s00066-025-02440-w","DOIUrl":"10.1007/s00066-025-02440-w","url":null,"abstract":"<p><strong>Purpose: </strong>Modern involved-site radiotherapy (ISRT) for Hodgkin lymphoma decreases toxicity through reduced field sizes and radiation doses. However, in pregnancy, the therapeutic benefit has to be weighed against putative harm to the mother and the fetus, as even small doses may have deleterious effects. We conducted a phantom-based simulation to analyze uterine dose exposure from cervical and mediastinal ISRT.</p><p><strong>Methods: </strong>Cervical and mediastinal ISRT target volumes were contoured to calculate three comparison plans (3D-conformal radiotherapy [3D-CRT], intensity-modulated radiotherapy [IMRT], volumetric intensity-modulated arc therapy [VMAT]). Thermoluminescent dosimeters (TLD) were placed within a humanoid Alderson phantom to simulate early and late pregnancy. Overall, six measurements (two for every radiotherapy plan) with 38 TLD were conducted.</p><p><strong>Results: </strong>In early pregnancy, cervical ISRT treatment of 19.8 Gray (Gy) resulted in median fetal exposures of 8.8 mGy, 15.4 mGy, and 9.9 mGy for 3D-CRT, IMRT, and VMAT, respectively, with significant differences between the three techniques (p < 0.001) and increased doses in late pregnancy (p < 0.001). For mediastinal ISRT (19.8 Gy), early pregnancy doses were 44 mGy, 63.8 mGy, and 60.5 mGy for 3D-CRT, IMRT, and VMAT, respectively, again with significant differences (p < 0.001) and a significant increase (p < 0.001) in late pregnancy. In comparison, values of 214.2 mGy (3D-CRT), 249.9 mGy (IMRT), and 249.9 mGy (VMAT) were reached using 30.6 Gy, with significant differences between 3D-CRT and VMAT (p < 0.001), 3D-CRT and IMRT (p < 0.001), and IMRT and VMAT (p = 0.004).</p><p><strong>Conclusion: </strong>Using RT during pregnancy may have deleterious effects on the fetus and should be deferred until after birth whenever possible. Theoretical uterine RT doses are low overall and only exceeded safety thresholds with higher-dose intensity-modulated plans. The indication for RT in pregnancy always requires careful risk-benefit consideration and individualized planning.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1279-1288"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12700992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Does SBRT still have a role to play in nodal oligorecurrent prostate cancer or is ENRT with ADT the new standard? : An interpretation of the PEACE V-STORM trial].","authors":"Niklas Recknagel, Sebastian Adeberg","doi":"10.1007/s00066-025-02458-0","DOIUrl":"10.1007/s00066-025-02458-0","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1317-1319"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial experience with MR-guided adaptive spinal stereotactic radiotherapy: a new indication for the MR-linac.","authors":"Neris Dincer, Teuta Zoto Mustafayev, Ceren Atahan, Gorkem Gungor, Gamze Ugurluer, Mehmet Ufuk Abacioglu, Enis Ozyar, Banu Atalar","doi":"10.1007/s00066-025-02401-3","DOIUrl":"10.1007/s00066-025-02401-3","url":null,"abstract":"<p><strong>Background and purpose: </strong>Stereotactic body radiotherapy (SBRT) is associated with good local control and symptom relief in the management of spinal metastases. Delivery of ablative doses and re-irradiation is challenged by spinal cord toxicity. We hypothesized that lower spinal cord doses as well as better target coverage could be yielded with stereotactic magnetic resonance-guided adaptive radiotherapy (SMART).</p><p><strong>Materials and methods: </strong>Institutional records were reviewed to retrieve patients who received online MR-guided SBRT for spinal metastases. Each fraction was reviewed to determine the necessity of adaptive planning, to identify reasons for violations that required adaptive planning, and to assess the spinal cord dose. The study also evaluated how adaptive planning contributed to reducing spinal cord doses.</p><p><strong>Results: </strong>A total of 34 patients with 61 lesions were included. The treatment intent was definitive for 47 (77.1%), palliative for 12 (19.7%), and postoperative for two (3.3%) lesions. The median prescribed Biological Equivalent Dose (BED)₁₀ was 51.3 Gy. Treatment plans often required adaptive adjustments (81.8%). Adaptive planning significantly improved target coverage (median PTV coverage 92.75% vs. 95%; p < 0.001) and reduced spinal cord D_max (median spinal cord D_max constraint: 7.3 Gy, median predicted spinal cord D_max: 7.76, and median adaptive spinal cord D_max 6.18; p < 0.001). Lesion-based median follow-up from irradiation was 7.5 months (range: 1-46 months). One-year LPFS was 94.3%. Six lesions progressed and none of the progressed lesions received a dose above the median BED₁₀ of 51.3 Gy.</p><p><strong>Conclusion: </strong>Herein we present our institutional experience with SMART for spinal bone metastases. According to our results, adaptive planning yields better target coverage as well as lower spinal cord doses compared to the predicted plan, which translates into a feasible method for delivering SBRT. Future prospective studies evaluating spinal SMART are awaited.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1289-1295"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12701034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Travel distance and potential disparities in palliative radiotherapy access for cancer patients in Victoria, Australia.","authors":"Maike Trommer, Piers Gillett, Fanny Franchini, Karen Trapani, Colin Hornby, Skye Abraham, Dishan Herath, Karla Gough, Keith Donohoe, Phillip Tran, Farshad Foroudi, Maarten IJzerman, Richard Khor","doi":"10.1007/s00066-025-02418-8","DOIUrl":"10.1007/s00066-025-02418-8","url":null,"abstract":"<p><strong>Background: </strong>Palliative radiotherapy (PRT) is crucial for improving quality of life in patients with advanced-staged cancer. This large data analysis investigates the travel distances and potential disparities in PRT access especially focusing on the burden of excess travel for palliative cancer patients in Victoria, Australia.</p><p><strong>Methods: </strong>Using a state-wide linked dataset from the PRedicting the health economic IMPact of new and current Cancer Treatments (PRIMCAT) research program, we analysed the estimated road travel distance (ERTD) and potential excess travel distance (PETD) as well as received radiotherapy fractions for 29,807 PRT patients being treated from 2010-2019. We examined disparities by socioeconomic status (SEIFA) and remoteness (RA) of the residential area of PRT patients, and receiving treatment at a public or private centre.</p><p><strong>Results: </strong>The average one-way ERTD for all PRT patients was 43 km, with variations based on SEIFA and RA. Patients in the lowest SEIFA quintile and those living in outer regional areas had the longest ERTD. Approximately 50% did not receive treatment at the closest facility, with a mean PETD of 27.9 km for private and 24.3 km for public facility patients. Fractionation patterns showed no significant reduction in the number of fractions with increased travel distance. Patients at private facilities received more fractions on average (8.49) compared to those at public facilities (5.91).</p><p><strong>Conclusion: </strong>This study highlights potential disparities in PRT access in Victoria, with patients living in socioeconomically disadvantaged and remote regions facing longer travel distances and excess travel. These findings underscore the need for strategic referral practices and further research to optimise equitable access to PRT.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1296-1305"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12701006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144969734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}